AnaptysBio, Inc (ANAB)

Etorro trading 970x250
AnaptysBio, Inc (ANAB) Logo

About AnaptysBio, Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Address: 10421 Pacific Center Court, San Diego, CA, United States, 92121

AnaptysBio, Inc News and around…

Latest news about AnaptysBio, Inc (ANAB) common stock and company :

Analysts Forecast 20% Upside For The Holdings of AFSM
11 Aug, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.05 per unit.

Analyst Forecasts Just Became More Bearish On AnaptysBio, Inc. (NASDAQ:ANAB)
10 Aug, 2022 Yahoo! Finance

Market forces rained on the parade of AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders today, when the analysts downgraded...

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
08 Aug, 2022 Yahoo! Finance

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
08 Aug, 2022 Yahoo! Finance

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in Q1 2023 SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
05 Aug, 2022 Yahoo! Finance

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT. A live audio webcast of the presentation will be ava

Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
08 Jul, 2022 Yahoo! Finance

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Analysts See 35% Gains Ahead For The Holdings of AFSM
05 Jul, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.26 per unit.

AnaptysBio (NASDAQ:ANAB) shareholders are up 11% this past week, but still in the red over the last three years
24 Jun, 2022 Yahoo! Finance

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But that...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
07 Jun, 2022 FinancialContent

Gainers Kiromic BioPharma (NASDAQ:KRBP) shares increased by 151.7% to $0.7 during Tuesday's pre-market session. The ...

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
02 Jun, 2022 Yahoo! Finance

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m. ET

Stocks That Hit 52-Week Lows On Thursday
02 Jun, 2022 FinancialContent

During theThursday's session, 100 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week ...

Stocks That Hit 52-Week Lows On Friday
27 May, 2022 FinancialContent

During Friday's session, 59 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week ...

Short Volatility Alert: AnaptysBio, Inc.
26 May, 2022 FinancialContent

On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went ...

AnaptysBio's Return On Capital Employed Insights
24 May, 2022 FinancialContent

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting ...

Look Under The Hood: AFSM Has 33% Upside
24 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.69 per unit.

Notable Friday Option Activity: RILY, MARA, ANAB
20 May, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in B. Riley Financial Inc (RILY), where a total of 3,042 contracts have traded so far, representing approximately 304,200 underlying shares..

Downgrade: Here's How Analysts See AnaptysBio, Inc. (NASDAQ:ANAB) Performing In The Near Term
10 May, 2022 Yahoo! Finance

One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...

Notable Thursday Option Activity: CROX, W, ANAB
05 May, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Crocs Inc (CROX), where a total of 17,406 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 128.8% of CROX's average daily trading volume over the past month of 1.4 million shares..

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
04 May, 2022 Yahoo! Finance

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
04 May, 2022 Yahoo! Finance

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing imsidolimab GEMINI-1 Phase 3 trial in GPP is anticipated in Q4 2023Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in H1 2023Ended Q1 2022 with approximately $596.8 million in cash with anticipated 2022 net cash burn of $90 to $

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
28 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Seeks FDA Emergency ...

AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
28 Apr, 2022 FinancialContent

AnaptysBio Inc(NASDAQ: ANAB)announced topline datafrom a Phase 1 trial of ANB032, an anti-BTLA agonist ...

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
27 Apr, 2022 Yahoo! Finance

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trialsANB032 IND filing in an initial proof-of-concept Phase 2 trial is anticipated in the second half of 2022Imsidolimab (anti-IL-36R Ab) top-line data from the Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in the third quarter of 2022 SAN DI

AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
26 Apr, 2022 Yahoo! Finance

AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Implied AFSM Analyst Target Price: $31
24 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.16 per unit.

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022
22 Mar, 2022 FinancialContent

Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, ...

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
22 Mar, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Keytruda ...

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
21 Mar, 2022 Yahoo! Finance

Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
15 Mar, 2022 Yahoo! Finance

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
15 Mar, 2022 FinancialContent

AnaptysBio Inc's(NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acnedid not demonstrate ...

AnaptysBio, Inc (ANAB) is a NASDAQ Common Stock listed in , ,

970x250